Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
Tebotelimab (previously known as MGD013) is an investigational, bispecific DART® molecule designed to independently or coordinately block PD-1 and LAG-3 checkpoint molecules to sustain or restore the function of exhausted T cells for the treatment of cancer. Monoclonal antibodies that target the immune checkpoints Lymphocyte-activation gene 3 (LAG-3) and PD-1 may have enhanced clinical activity when given in combination. Tebotelimab has been engineered to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function.
Clinical Development
Tebotelimab is currently being studied in combination with enoblituzumab (an investigational monoclonal antibody that targets B7-H3) in patients with squamous cell carcinoma of the head and neck who are PD-L1 negative.
Our Rights
Zai Lab has development and commercialization rights in Greater China. MacroGenics retains full development and commercialization rights in all other territories.
Clinical Trials
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer (NCT04634825)
- Tebotelimab (MGD013) Phase 1 dose expansion study (NCT03219268)
Presentations & Publications
Relevant Publications and Presentations can be found at https://dev.macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.